---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-004556"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2026-07-28T18:30:39+00:00"
generated_at: "2026-07-28T18:31:06.124445+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioNexus advances VitaGuard MRD rollout in SE Asia after China visit; targets 2026 deployment

## Summary
- Working visit to Tongshu Gene facilities in Shanghai and Changzhou; reviewed implementation for SE Asia under license.
- VitaGuard is a tumor-naive fixed-panel liquid biopsy for MRD; currently in paid commercial use in China.
- BioNexus holds exclusive license for 10 SE Asian markets (pop. 680M); also owns ~15% of Fidelion holding international rights.
- Target cost per test under $300; initial deployment targeted in select SE Asian medical hubs during 2026.
- Fidelion in discussions with partners for markets outside SE Asia; no definitive agreement yet.

## SEC filing metadata
- accession: 0001477932-26-004556
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2026-07-28T18:30:39+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793226004556/0001477932-26-004556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793226004556/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-004556
- JSON: https://secwatch.observer/filing/0001477932-26-004556.json
- Plain text: https://secwatch.observer/filing/0001477932-26-004556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.